,
Department of Endocrinology and Metabolism, School of Medicine, Trakya University , Edirne , Turkey
Department of Endocrinology and Metabolism, School of Medicine, Trakya University , Edirne , Turkey
Department of Endocrinology and Metabolism, School of Medicine, Trakya University , Edirne , Turkey
Department of Internal Medicine, School of Medicine, Trakya University , Edirne , Turkey
Department of Genetic, School of Medicine, Trakya University , Edirne , Turkey
Department of Pathology, School of Medicine, Trakya University , Edirne , Turkey
Department of Pathology, School of Medicine, Trakya University , Edirne , Turkey
Department of Nuclear Medicine, School of Medicine, Trakya University , Edirne , Turkey
Department of Surgery, School of Medicine, Trakya University , Edirne , Turkey
Department of Endocrinology and Metabolism, School of Medicine, Trakya University , Edirne , Turkey
Aim
BRAF mutation inhibits many tumour suppressor genes, increases pro-angiogenic molecules and reduces radioactive iodine uptake of tumour in papillary thyroid cancer (PTC), giving it more aggressive clinical characteristics. In this study, we aimed to evaluate the effect of BRAF V600E mutation on the clinicopathological features in patients with PTC.
Methods
The laboratory and clinical findings of 256 PTC patients who were referred to our clinic between 2007 and 2017 were assessed. Subjects involved in the study were divided into two groups depending on the presence of BRAF V600E mutation. Results
BRAF V600E mutation testing gave positive results for 65 (25.4%) out of 256 patients. No significant correlation between BRAF V600E mutation, age and gender was detected. There was no difference between the groups in terms of tumour variant, tumour localization, tumour focality, and perineural invasion. In terms of histopathologic characteristics, presence of tumour capsular invasion (p=0.027), extrathyroidal extension (ETE) (p=0.002), absence of pathologically detected lymphocytic thyroiditis (p=0.006) and radio iodine I-131 treatment (p=0.001) were significantly higher in BRAF V600E (+) patients. During a followup period, four patients with BRAF V600E (+) and two patients with BRAF V600E (-) status underwent lateral neck dissection due to lymph node metastasis (p=0.01).
Conclusion
The presence of BRAF V600E mutation was proved to be a poor prognostic factor. However, in order to further assess the prognostic effect of BRAF V600E mutation in this group of patients and particularly its effect on mortality, long term followup results must be evaluated.
This work is licensed under a Attribution-NonCommercial-NoDerivatives 4.0 International 
3
Yang Liu, Ting-Yu Chen, Zhi-Yan Yang, Wei Fang, Qian Wu, Chao Zhang
(2020)
Identification of hub genes in papillary thyroid carcinoma: robust rank aggregation and weighted gene co-expression network analysis
Journal of Translational Medicine, 18(1)
10.1186/s12967-020-02327-7
Azadeh Etemadzadeh, Pouya Salehipour, Fatemeh Movahedi Motlagh, Masoomeh Khalifeh, Adnan Asadbeigi, Mina Tabrizi, Reza Shirkouhi, Mohammad Hossein Modarressi
(2024)
An Optimized CRISPR/Cas12a Assay to Facilitate the BRAF V600E Mutation Detection
Journal of Clinical Laboratory Analysis, 38(21)
10.1002/jcla.25101
Aomei Zhao, Jing Zhang, Yan Liu, Xi Jia, Xueni Lu, Qi Wang, Ting Ji, Lulu Yang, Jianjun Xue, Rui Gao, Yan Yu, Aimin Yang
(2021)
Synergic radiosensitization of sinomenine hydrochloride and radioiodine on human papillary thyroid carcinoma cells
Translational Oncology, 14(10)
10.1016/j.tranon.2021.101172The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.